The following is a summary of “Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging ...

A study was undertaken to assess the effectiveness of this therapy as an adjunctive tool in the management of asthma in adult patients who remained symptomatic on moderate to high doses of inhaled ...

Chime Biologics, a leading global CDMO that enables its partners' success in biologics, today announced its continued ...

The leading Severe Asthma Companies such as Kinaset Therapeutics, Bio-Thera Solutions, CSPC ZhongQi Pharmaceutical Technology, AB Science, GlaxoSmithKline, Oneness Biotech, Biosion, Lanier ...

Individuals with moderate to severe obstructive sleep apnea had increased odds of having neovascular AMD. Nocturnal hypoxia may be a modifiable risk factor for neovascular AMD. Perspective from ...

Airsupra (PT027), a new asthma rescue treatment developed by AstraZeneca (AZ) and development partner Avillion, has been approved by the US Food and Drug Administration (FDA). A first-in-class ...

Nemluvio has received approval from the European Commission to treat moderate to severe atopic dermatitis and prurigo nodularis in the European Union, Galderma announced in a press release.

GSK's new long-acting drug candidate for severe asthma, depemokimab ... achieve a significant reduction in the annualised rate of moderate or severe exacerbations in the MATINEE trial in chronic ...

EC approves MRK's Welireg for two indications. FDA grants priority review to SNY and REGN's Dupixent sBLA for bullous pemphigoid.

For this reason, ipratropium was not recommended in asthma, except in acute severe asthma management ... The first large study on unselected moderate asthmatics showed that tiotropium was as ...